Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$-1.28
EPS est.
$-1.51
EPS surprise
+15.46%
1-day move
-1.60%
Merck's earnings report showed a better-than-expected EPS result, which was a positive surprise for investors. However, the stock still declined by 1.6% on the day, indicating that the market may have had concerns about other aspects of the company's performance or future outlook. The lack of revenue data and guidance may have contributed to the stock's negative reaction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.28 | $-1.47 | +15.46% |
| Revenue | N/A | $15.8B | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Merck & Co., Inc. is a major player in the pharmaceuticals sector, focusing on innovative medicines and vaccines. With a market cap of $272 billion, the company is significant in the healthcare industry, particularly in areas like oncology and infectious diseases.
Last quarter
In the last quarter, Merck reported an EPS of $2.04, slightly beating expectations. The stock reacted positively, gaining 2.18% the next day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+11.20%
Avg 1-day reaction
-1.42%
Analysts are expecting a challenging quarter for Merck, with a consensus EPS of -1.47, indicating potential losses. Revenue expectations are set at $15.8 billion, reflecting cautious optimism.
Bull case
If Merck can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.
Bear case
Conversely, if the company reports a larger loss than anticipated or revenue falls short, it could raise concerns about its market position and future growth.
Key metrics to watch
Earnings Per Share (EPS)
-1.47EPS is a key indicator of a company's profitability and is closely watched by investors.
Revenue
15.8BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Merck's EPS come in better than the consensus estimate of -1.47?
This figure will be crucial in assessing the company's profitability and market confidence.
Q2
How does Merck's revenue of $15.8 billion compare to expectations?
Revenue performance will indicate demand for Merck's products and overall business health.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The Street may be underestimating Merck's ability to recover from recent challenges, particularly in oncology sales.
Supporting evidence
Merck has consistently beaten EPS estimates in the past, suggesting potential for a surprise.
The options market is pricing a larger move than historical averages, indicating investor uncertainty.
Recent insider buying may suggest confidence in the company's recovery.
Key risk
If Merck's oncology sales show unexpected strength, it could significantly alter the earnings outlook.
Pre-commit to what would confirm each case.
The market is debating whether Merck can maintain profitability amidst competitive pressures and market dynamics.
Bull confirmed if
An EPS of -1.20 or better would confirm the bull case.
Bear confirmed if
An EPS worse than -1.70 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±4.8%
Historical Avg
±2.4%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±4.8% while MRK has averaged ±2.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
23.6%
Smart-money positioning from the most recent 13F filings.
Institutional
83.03%
of float
Insider
0.06%
of float
Holders
4,805
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
226,999,837 sh · $32.4B
9.20%
0.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Merck beats EPS expectations, history suggests the stock could rise around 2.1% based on past performance.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical patterns indicating a potential drop around 2.1%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
1 buy·1 sell
Members
1
House only
Est. Notional
$16,002.00–$65,000.00
disclosed dollar ranges
Most Active Members
2 trades
The lines on the call that would change the story.
Vanguard Capital Management LLC
161,323,174 sh · $23.0B
6.54%
0.2%
State Street Corporation
120,413,256 sh · $17.2B
4.88%
0.9%
Wellington Management Group, LLP
86,249,283 sh · $12.3B
3.50%
2.3%
Vanguard Portfolio Management LLC
67,738,969 sh · $9.7B
2.75%
0.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Mixed
Recent Transactions
Traded Sep 24, 2026 · disclosed Oct 7, 2026
$1,001.00–$15,000.00
Traded Aug 19, 2026 · disclosed Sep 9, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.